In addition to that these agents contribute to substantial weight loss, decreased NT-ProBNP levels and reduction in HF hospitalization, MACE and cardiovascular mortality, SBP and arrhythmias, indicating reduced cardiac stress and decreased healthcare expenses with improved patient prognosis
Our findings align with the previous meta-analysis done by Avogaro et al., which specifies improvement in NT-ProBNP level by GLP-1RA drugs.20 Also, our findings strengthen the findings in secondary analysis of STEP-HFpEF and STEP-HFpEF DM trials by Petrie et al., where they concluded similar improvements.21 The KCCQ-CSS score assesses patients health perceptions, encompassing physical restrictions, symptoms, social limitations, and quality of life, and is crucial for HFpEF patients.22 A change of 5 points is considered clinically meaningful.23 Our meta-analysis found that GLP-1RA therapy considerably improves quality of life, as shown by higher KCCQ-CSS scores
Real members, real results
They concluded that ALCAR exhibited anti-fibrotic and anti-inflammatory effects in in-vitro and in-vivo models of Peyronie's Disease
Why Choose Contour Clinique Med Spa for Medical Weight Loss
Personalized Medical Review Treatment starts with your health history, medications, weight history and individual goals